Open AccessIndirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
Author(s) -
Karen L. Reckamp,
Huamao Mark Lin,
Holly Cranmer,
Yanyu Wu,
Pingkuan Zhang,
Laura Walton,
Stephen Kay,
Allie Cichewicz,
Binod Neupane,
Kyle Fahrbach,
Sanjay Popat,
D. Ross Camidge
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0194
Subject(s) - alectinib , crizotinib , medicine , lung cancer , oncology , anaplastic lymphoma kinase , ceritinib , alk inhibitor , clinical trial , tyrosine kinase inhibitor , cancer , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom